[HTML][HTML] The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
AM Di Giacomo, M Lahn, AMM Eggermont… - European Journal of …, 2023 - Elsevier
Abstract The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the
Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer …
Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer …
[HTML][HTML] The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune …
C Kalla, G Ott, F Finotello, K Niewola-Staszkowska… - Translational …, 2024 - Elsevier
Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a
promising therapeutic strategy. We here investigated the effect of the novel and highly …
promising therapeutic strategy. We here investigated the effect of the novel and highly …
Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations
X Liu, Z Run‐hua, J Pan, Z Li, L Yu… - Pigment Cell & …, 2024 - Wiley Online Library
Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults.
Although primary UM can be effectively controlled, a significant proportion of cases (40% or …
Although primary UM can be effectively controlled, a significant proportion of cases (40% or …
IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Z Johnson, C Tarantelli, E Civanelli, L Cascione… - Cancer Research …, 2023 - AACR
PI3K delta (PI3Kδ) inhibitors are used to treat lymphomas but safety concerns and limited
target selectivity curbed their clinical usefulness. PI3Kδ inhibition in solid tumors has …
target selectivity curbed their clinical usefulness. PI3Kδ inhibition in solid tumors has …
[HTML][HTML] Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers
P Spiliopoulou, P Kaur, T Hammett… - Cancer Drug …, 2024 - ncbi.nlm.nih.gov
Primary or secondary (ie, acquired) resistance is a common occurrence in cancer patients
and is often associated with high numbers of T regulatory (T reg) cells (CD4+ CD25+ …
and is often associated with high numbers of T regulatory (T reg) cells (CD4+ CD25+ …
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib
L van der Veen, M Schmitt… - … Journal of Toxicology, 2023 - journals.sagepub.com
Roginolisib (IOA-244) is a novel, non-ATP competitive phosphoinositide-3-kinase (PI3K)
delta inhibitor that regulates Akt/mTOR signaling. Roginolisib was administered once daily …
delta inhibitor that regulates Akt/mTOR signaling. Roginolisib was administered once daily …